Updated: 'Semi-retired' analyst Geoffrey Porges departs SVB to lead finances at a drug discovery shop
Geoffrey Porges has ended his two-decade run as a biotech analyst, as the former SVB Securities vice chair began as CFO of Schrödinger on Thursday.
The long-running analyst, who previously headed up vaccines marketing at Merck before the turn of the millennium, will lead the financial operations of the 700-employee company as Schrödinger broadens its focus from a drug discovery partner to also building out an in-house pipeline, with clinical trial No. 1 set to begin next quarter.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.